3.0.0 1405 2025-07-30T21:27:37Z 2025-07-30T21:27:37Z House H HR 2025-02-18 119 <pre>[Congressional Record Volume 171, Number 32 (Tuesday, February 18, 2025)][House]From the Congressional Record Online through the Government Publishing Office [<a href="https://www.gpo.gov">www.gpo.gov</a>]By Mr. BUCHANAN:H.R. 1405.Congress has the power to enact this legislation pursuantto the following:Article 1, section 8[Page H723]</pre> hsif00 Energy and Commerce Committee House Standing Referred To 2025-02-18T18:04:20Z 2025-02-18 Referred to the House Committee on Energy and Commerce. IntroReferral H11100 2 House floor actions hsif00 Energy and Commerce Committee 2025-02-18 Introduced in House IntroReferral Intro-H 9 Library of Congress 2025-02-18 Introduced in House IntroReferral 1000 9 Library of Congress B001260 Rep. Buchanan, Vern [R-FL-16] Vern Buchanan R FL 16 N D000032 Rep. Donalds, Byron [R-FL-19] Byron Donalds R FL 19 2025-02-18 True Health Administrative law and regulatory procedures 2025-07-09T14:00:37Z Congressional oversight 2025-07-09T14:00:49Z Environmental regulatory procedures 2025-07-09T14:00:43Z Government studies and investigations 2025-07-09T14:00:16Z Manufacturing 2025-07-09T14:00:22Z Prescription drugs 2025-07-09T14:00:27Z Health 2025-03-17T14:05:01Z

00 2025-02-18 Introduced in House 2025-07-30T21:26:28Z <p><strong>Enhancing Domestic Drug Manufacturing Competitiveness Act</strong></p><p>This bill requires the Government Accountability Office (GAO) to study and report to Congress on key regulatory barriers to pharmaceutical manufacturing in the United States.&nbsp;</p><p>Specifically, GAO must identify and assess, including by engaging stakeholders, barriers that impede expansion or siting of pharmaceutical manufacturing facilities in the United States or make the United States less competitive than other countries as a location for such facilities. GAO must consider (1) whether environmental or other regulations significantly delay and increase the cost of expanding or siting pharmaceutical manufacturing facilities in the United States; (2) the potential impact of environmental and other regulations on pharmaceutical supply chain resiliency; and (3) specific actions for regulators to address the identified barriers.&nbsp;</p><p>Finally, the report must include recommendations for streamlining regulatory barriers and facilitating technological solutions to foster U.S. pharmaceutical manufacturing.&nbsp;</p>

Display Title 45 2025-03-13T04:23:35Z Short Title(s) as Introduced 101 2025-03-13T04:23:25Z Introduced in House IH Official Title as Introduced 6 2025-03-13T04:20:34Z Introduced in House IH Introduced in House 2025-02-18T05:00:00Z https://www.govinfo.gov/content/pkg/BILLS-119hr1405ih/xml/BILLS-119hr1405ih.xml 2025-02-18 Referred to the House Committee on Energy and Commerce. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.